Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
Eloxx Pharmaceuticals Shares Program Report on Phase 2 Alport Trial involving ELX-02
14 September 2023
Eloxx Pharmaceuticals, Inc. provided new information on the development of ELX-02 in the context of handling Alport syndrome caused by nonsense mutations.
Drug Insights
4 min read
Decoding Lacosamide: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
14 September 2023
This article summarized the latest R&D progress of Lacosamide, the Mechanism of Action for Lacosamide, and the drug target R&D trends for Lacosamide.
Drug Insights
4 min read
Deep Scientific Insights on Isosorbide Dinitrate's R&D Progress
14 September 2023
This article summarized the latest R&D progress of Isosorbide Dinitrate, the Mechanism of Action for Isosorbide Dinitrate, and the drug target R&D trends for Isosorbide Dinitrate.
Latest Hotspot
4 min read
Janssen presents an application for Marketing Authorisation to the EMA, requesting endorsement for Erdafitinib's utilization in the management of patients
14 September 2023
Janssen Pharmaceuticals filed a Marketing Authorisation Application with EMA to get approval for Erdafitinib. The drug is for adult patients with advanced or metastatic urothelial carcinoma, showing progression after a PD-1/PD-L1 inhibitor therapy, with susceptible FGFR3 mutations.
Drug Insights
4 min read
An In-depth Analysis of Icosapent Ethyl's R&D Progress
14 September 2023
This article summarized the latest R&D progress of Icosapent Ethyl, the Mechanism of Action for Icosapent Ethyl, and the drug target R&D trends for Icosapent Ethyl.
Valuable Targets
7 min read
Research Progress and Future of KRAS G12C Inhibitors
14 September 2023
Understanding the role of KRAS G12C is essential for developing targeted therapies that can specifically inhibit this mutation, offering potential treatment options for patients with KRAS G12C-mutated cancers.
Drug Insights
4 min read
Griseofulvin: Detailed Review of its Transformative R&D Success
14 September 2023
This article summarized the latest R&D progress of Griseofulvin, the Mechanism of Action for Griseofulvin, and the drug target R&D trends for Griseofulvin.
Latest Hotspot
3 min read
2023 WCLC | AstraZeneca's EGFR-TKI Osimertinib Mesylate New Indication Phase 1b Clinical Data Selected for Oral Presentation
14 September 2023
The FAVOUR study's interim analysis results on Alflutinib Mesylate for treating EGFR exon 20-insertion mutated NSCLC were orally presented at the 2023 WCLC. The drug is developed by Shanghai Allist Pharmaceuticals and ArriVent Biopharma.
Drug Insights
4 min read
Unleashing the Power of Flumazenil: A Comprehensive Review on R&D Breakthroughs
14 September 2023
This article summarized the latest R&D progress of Flumazenil, the Mechanism of Action for Flumazenil, and the drug target R&D trends for Flumazenil.
Bio Sequence
2 min read
Choose A Reliable Biological Sequence Database for Large Molecule Drug's FTO
14 September 2023
Research and development (R&D) efforts in biopharmaceuticals are high, cycles are long, and risks are significant. Companies in this industry heavily rely on core technologies, specialized talents, and intellectual property protection. Drug patents' freedom to operate (FTO) is crucial for determining whether drug candidates can be further commercialized.
Drug Insights
4 min read
A Comprehensive Review of Febuxostat's R&D Innovations
13 September 2023
This article summarized the latest R&D progress of Febuxostat, the Mechanism of Action for Febuxostat, and the drug target R&D trends for Febuxostat.
Latest Hotspot
4 min read
Chia Tai Tianqing Pharmaceutical initiates global multicenter phase III clinical trials for the pan-PPAR agonist Lanifibranor
13 September 2023
On Sept 11, 2023, Chia Tai Tianqing Pharmaceutical launched a global phase III trial, evaluating Lanifibranor's efficacy and safety in adult NASH patients with stage 2/3 hepatic fibrosis, excluding cirrhosis.